Patents Assigned to Augusta University Research Institute, Inc.
-
Publication number: 20210361597Abstract: Disclosed herein as ibuprofen hybrid conjugates and methods of their use to reduce inflammation, pain, and fever. The ibuprofen conjugates have potent anti-inflammatory and analgesic properties with low potential for ulcerogenic activity. An exemplary compound is an ibuprofen-amino acid-4-aminophenol hybrid. Also disclosed are methods of treating or reducing inflammation, pain, and fever in a subject.Type: ApplicationFiled: May 19, 2021Publication date: November 25, 2021Applicant: Augusta University Research Institute, Inc.Inventor: Siva PANDA
-
Publication number: 20210335451Abstract: Disclosed herein are methods of staging, treating and making prognostic prediction of, monitoring of therapeutic outcome for treatment of cervical carcinoma in a patient in need thereof by quantifying gene expression in a sample, wherein the genes include 40 high risk genes; calculating the subject's survival risk score by determining the gene expression levels and their inter-dependence using machine learning (ML) and artificial intelligence. The survival risk category of a patient is determined by the consensus or plurality voting of a large number of ML models that individually have excellent predictive potential, thus providing a very robust prognostic biomarker for cervical carcinoma.Type: ApplicationFiled: April 26, 2021Publication date: October 28, 2021Applicant: Augusta University Research Institute, Inc.Inventor: Jin-Xiong SHE
-
Publication number: 20210310074Abstract: The application provides methods of prognosing and classifying uterine serous carcinoma (USC) patients into poor survival groups or good survival groups and for predicting response to therapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application.Type: ApplicationFiled: February 11, 2021Publication date: October 7, 2021Applicant: Augusta University Research Institute, Inc.Inventors: Jin-Xiong She, Lynn Tran
-
Publication number: 20210299185Abstract: The invention relates to the treatment of various injuries, disorders, dysfunctions, diseases, and the like of the brain with MAPCs, particularly in some aspects, to the treatment of the same resulting from hypoxia, including that caused by systemic hypoxia and that caused by insufficient blood supply. In some further particulars the invention relates, for example, to the treatment of hypoxic ischemic brain injury with MAPCs, in children for example, and to the treatment of cortical infarcts and stroke with MAPCs in adults, for example.Type: ApplicationFiled: June 10, 2021Publication date: September 30, 2021Applicants: ABT Holding Company, AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.Inventors: Robert W. MAYS, Robert J. DEANS, David C. HESS, James E. CARROLL, Cesar V. BORLONGAN
-
Publication number: 20210251609Abstract: It has been discovered that even mild changes in cerebrospinal fluid (CSF) pressure or intracranial pressure (ICP) can be detected immediately as evidenced by distortions in the ONS surface structure. Further, the changes in the ONS persist after the CSF pressure has returned to normal. The stability of ONS distortions provides a means of detecting transient changes in brain pressure even when the use of the diagnostic ultrasound is delayed. One embodiment provides systems and methods for detecting or diagnosing brain injury by detecting distortions or deformations of the ONS, preferably using ultrasound.Type: ApplicationFiled: April 7, 2021Publication date: August 19, 2021Applicant: Augusta University Research Institute, Inc.Inventor: Matthew LYON
-
Publication number: 20210196817Abstract: It has been discovered that PIK3? (PIK3delta) selectively modulates the activation and proliferation of natural Tregs. Methods of modulating immune responses by modulating PIK3? bioavailability or biological activity are provided.Type: ApplicationFiled: December 9, 2020Publication date: July 1, 2021Applicant: Augusta University Research Institute, Inc.Inventors: Samir N. KHLEIF, Mikayel MKRTICHYAN
-
Publication number: 20210196673Abstract: Modified green tea polyphenol compositions and their methods of use in treating and preventing SARS-CoV-2 infections are provided. An exemplary green tea polyphenol composition includes (?)-epigallocatechin-3-gallate that can be esterified with a C1-C30 group in at least one position and a carrier such as glycerol. The modified green tea polyphenol compositions can be used to treat and prevent SARS-CoV-2 infections without coming into contact with the viral cell.Type: ApplicationFiled: February 23, 2021Publication date: July 1, 2021Applicant: Augusta University Research Institute, Inc.Inventor: Stephen D. Hsu
-
Patent number: 11041011Abstract: T cell receptors that specifically recognize hAFP158 and methods of their use are provided.Type: GrantFiled: May 2, 2018Date of Patent: June 22, 2021Assignees: Augusta University Research Institute, Inc., National Institutes of Health (NIH), U.S. Dept. of Health And Human Services (DHHS), U.S. Government NIH Division of Extramural Inventionsl and Technology Resources (DEITR)Inventors: Yukai He, Wei Zhu, Esteban Celis, Yibing Peng, Lan Wang
-
Publication number: 20210162076Abstract: An aptamer platform capable of efficiently delivering and silencing one, two or more genes in vivo or in vitro is provided. Methods of using the aptamer compositions for selectively targeting cells to down-regulate the expression of multiple genes are also provided.Type: ApplicationFiled: February 9, 2021Publication date: June 3, 2021Applicant: Augusta University Research Institute, Inc.Inventor: Hong Yan LIU
-
Patent number: 11021540Abstract: Antibodies and antigen binding fragments thereof are provided that immunospecifically bind to PD-1, preferably human or mouse PD-1, and induce or promote an immune response that activates immune cell proliferation or activity. Contrary to the existing paradigm that PD-1 exclusively promotes a suppressive immune response, the disclosed antibodies and antigen binding fragments thereof, immunospecifically bind to PD-1 and cause an activating signal to be delivered to the immune cell that activates the immune cell rather than suppressing the immune cell. In one embodiment, the disclosed antibodies and antigen binding fragments thereof specifically bind to PD-1 expressed on immune cells. The binding of the disclosed antibodies and antigen binding fragments thereof to PD-1 on immune cells causes an activating signal to be transmitted into the immune cell, for example a signal that enhances or promotes cytokine production and/or activation of immune cell proliferation.Type: GrantFiled: September 7, 2018Date of Patent: June 1, 2021Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.Inventors: Samir Khleif, Mikayel Mkrtichyan
-
Patent number: 11013735Abstract: Methods of selectively inhibiting Akt3 are provided. It has been discovered that 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide selectively inhibits Akt3. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide can be used for modulating immune responses.Type: GrantFiled: October 2, 2019Date of Patent: May 25, 2021Assignee: Augusta University Research Institute, Inc.Inventors: Samir N. Khleif, Mikayel Mkrtichyan
-
Publication number: 20210130782Abstract: CD206-positive M2 macrophage-targeting exosomes and methods of use thereof are provided. One embodiment provides a CD206-positive M2 macrophage-targeting exosome expressing a CD206 binding peptide and an Fc portion of IgG2b. In some embodiments, the CD206 binding peptide is encoded by a nucleic acid sequence having 95%, 99%, or 100% sequence identity to SEQ ID NO:2 and the IgG2b is encoded by a sequence having 95%, 99%, or 100% sequence identity to SEQ ID NO:6.Type: ApplicationFiled: October 28, 2020Publication date: May 6, 2021Applicant: Augusta University Research Institute, Inc.Inventors: Ali ARBAB, Mohammad Harun RASHID, Thaiz BORIN, Roxan ARA
-
Patent number: 10993888Abstract: Fluorescent nanoparticle compositions and methods of used for dental bonded restorations are provided herein.Type: GrantFiled: December 20, 2018Date of Patent: May 4, 2021Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.Inventors: Marcelo Giannini, Rafael Rocha Pacheco, Frederick Allen Rueggeberg, Jorge Rodrigo Soto Montero, Eduardo David Martinez, Ali Francisco Garcia Flores, Ailla Carla Rocha Acosta Lancellotti, Guilherme Gorgen Lesseux, Carlos Rettori, Ricardo Rodrigues Urbano
-
Patent number: 10987088Abstract: It has been discovered that even mild changes in cerebrospinal fluid (CSF) pressure or intracranial pressure (ICP) can be detected immediately as evidenced by distortions in the ONS surface structure. Further, the changes in the ONS persist after the CSF pressure has returned to normal. The stability of ONS distortions provides a method of detecting transient changes in brain pressure even when the use of the diagnostic ultrasound is delayed. One embodiment provides systems and methods for detecting or diagnosing brain injury by detecting distortions or deformations of the ONS, preferably using ultrasound.Type: GrantFiled: July 1, 2015Date of Patent: April 27, 2021Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.Inventor: Matthew Lyon
-
Publication number: 20210113512Abstract: Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (HbF) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce HbF expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (HBB) or an expression control sequence thereof. Pharmaceutical dosage units and dosage regimes for use in the disclosed methods are also provided.Type: ApplicationFiled: September 24, 2020Publication date: April 22, 2021Applicant: Augusta University Research Institute, Inc.Inventors: Vadivel Ganapathy, Pamela M. Martin
-
Patent number: 10980878Abstract: Compounds and compositions for selectively inhibiting Akt3 are provided. Methods of using the compounds are also provided. Because Akt3 modulates the suppressive function of natural Tregs and the polarization of induced Tregs, the disclosed compounds are useful for modulating immune responses.Type: GrantFiled: February 5, 2020Date of Patent: April 20, 2021Assignee: Augusta University Research Institute, Inc.Inventors: Samir N. Khleif, Mikayel Mkrtichyan, Iryna Lebedyeva, Thomas Albers
-
Patent number: 10960086Abstract: An aptamer platform capable of efficiently delivering and silencing one, two or more genes in vivo or in vitro is provided. Methods of using the aptamer compositions for selectively targeting cells to down-regulate the expression of multiple genes are also provided.Type: GrantFiled: December 28, 2018Date of Patent: March 30, 2021Assignee: Augusta University Research Institute, Inc.Inventor: Hong Yan Liu
-
Patent number: 10877047Abstract: The present invention includes methods for the detection of neurotransmission or developmental disorders, including, but not limited to, myasthenia gravis that is seronegative for autoantibodies to the acetylcholine receptor (AChR) and/or muscle specific tyrosine kinase (MuSK), the method including detecting autoantibodies that bind to LRP4, or an epitope thereof. Also included are methods for the treatment of an individual suffering from a neurotransmission disorder, the method including detecting in a bodily fluid of the individual autoantibodies that bind to LRP4, or an epitope thereof, and administering to the patient an effective amount an immunosuppressant and/or another appropriate therapeutic modality. Also included are antibodies that bind to autoantibodies to LRP4 and kits for the detection of neurotransmission or developmental disorders.Type: GrantFiled: January 29, 2018Date of Patent: December 29, 2020Assignee: AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.Inventors: Lin Mei, Wen-Cheng Xiong, Bin Zhang, Chengyong Shen
-
Patent number: 10822380Abstract: As disclosed herein, stapled peptides targeting the interaction interface between proteins that maintain the integrity of Wiskott-Aldrich syndrome protein family member 3 (WASF3) leads to destabilization of WASF3 and suppression of invasion. Disclosed are stapled peptides that inhibit the binding of Cytoplasmic FMR1-interacting protein 1 (CYFIP1) to either WASF3 or NCK-associated protein (NCKAP1). Also disclosed are methods for treating or suppressing invasion and metastasis of a cancer in a subject that involve administering to the subject a therapeutically effective amount of a stapled peptide disclosed herein.Type: GrantFiled: April 8, 2016Date of Patent: November 3, 2020Assignees: University of Georgia Research Foundation, Inc., Augusta University Research Institute, Inc.Inventors: Eileen J. Kennedy, John Cowell
-
Patent number: 10813905Abstract: Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (HbF) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce HbF expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (HBB) or an expression control sequence thereof. Pharmaceutical dosage units and dosage regimes for use in the disclosed methods are also provided.Type: GrantFiled: August 1, 2017Date of Patent: October 27, 2020Assignee: Augusta University Research Institute, Inc.Inventors: Vadivel Ganapathy, Pamela M. Martin